BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2015 10:55:00 AM | Browse: 202 | Download: 314
Publication Name World Journal of Immunology
Manuscript ID 12305
Country of Manuscript Source United States
Received
2014-07-01 09:34
Peer-Review Started
2014-07-01 13:55
To Make the First Decision
2014-09-28 14:00
Return for Revision
2014-09-29 17:39
Revised
2014-10-23 22:35
Second Decision
2014-11-12 13:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-11-19 11:09
Articles in Press
2014-11-19 11:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-03-26 19:08
Publish the Manuscript Online
2015-03-31 10:28
ISSN 2219-2824 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Immunology
Manuscript Type Review
Article Title Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches
Manuscript Source Invited Manuscript
All Author List Mira A Patel, Jennifer E Kim, Jacob Ruzevick and Michael Lim
Funding Agency and Grant Number
Correspondence To Michael Lim, MD, Associate Professor of Neurosurgery and Oncology, Department of Neurosurgery, the Johns Hopkins University School of Medicine, 600 N. Wolfe St., Phipps Building Rm 123, Baltimore, MD 21287, United States. mlim3@jhmi.edu
Keywords Programmed death-1; Cytotoxic T lymphocyte associated antigen-4; Ipilimumab; Nivolumab; Immune checkpoint
Core Tip Aggressive cancer growth is often characterized by tumor expression of molecules that co-opt effective immune responses through immune checkpoints. Clinical blockade of checkpoints programmed death-1 and cytotoxic T lymphocyte associated antigen-4 and has spurred the discovery of a number of immune checkpoints that may be inhibited in anticancer therapy. The clinical successes of checkpoint blockade have led to increasing interest in combining treatment modalities. Combination checkpoint blockade with chemoradiation has shown synergistic effects, and checkpoint blockade with bacterial vaccine vectors have produced increased immune responses in pre-clinical models. The future of immune checkpoint blockade may be as a powerful adjuvant alongside the current standard of care.
Publish Date 2015-03-31 10:28
Citation Patel MA, Kim JE, Ruzevick J, Lim M. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol 2015; 5(1): 1-15
Url http://www.wjgnet.com/2219-2824/full/v5/i1/1.htm
DOI http://dx.doi.org/10.5411/wji.v5.i1.1
Full Article (PDF) WJI-5-1.pdf
Full Article (Word) WJI-5-1.doc
Revised Manuscript 12305-Review.docx
Peer-review Report 12305-Peer review(s).pdf
Answering Reviewers 12305-Answering reviewers.pdf
Scientific Misconduct Check 12305-CrossCheck.jpg
Scientific Editor Work List 12305-Scientific editor work list.pdf
Copyright License Agreement 12305-Copyright assignment.pdf